Johnson & Johnson secured an FDA approval on Wednesday for a psoriasis pill it expects to become a megablockbuster. Regulators gave the green light to

Johnson & Johnson’s much-anticipated oral IL-23 drug, icotrokinra, has claimed FDA approval as Icotyde for first-line treatment of plaque psoriasis.

Always be in the clinic — those are the “ABCs” of biotech, drug development veteran Briggs Morrison tells Endpoints News. And that’s precisely where Morrison’s

Aspen Neuroscience said its experimental Parkinson’s disease treatment, made from a patient’s own cells, showed encouraging results in a small study. The clinical trial builds

The aligned regulatory pathway for UK drugs regulator MHRA and reimbursement authority NICE gets underway on 1st April.